Clinical Trials · NCT05371496
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- Mayo Clinic
- Enrollment
- 81
- Start date
- Sep 2022
- Locations
- 1 site, United States
- Primary endpoint
- Pulmonary Capillary Wedge Pressure (PCWP)